Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.
about
Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian miceCharacterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulationParkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's diseaseThe antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodentsRecent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.Group III metabotropic glutamate receptors and drug addictionA further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's diseaseThe Role of Group II Metabotropic Glutamate Receptors in the Striatum in Electroacupuncture Treatment of Parkinsonian Rats.Synthesis and neuroprotective effects of the complex nanoparticles of iron and sapogenin isolated from the defatted seeds of Camellia oleifera.
P2860
Q30450052-D771EEEF-59D3-4EBC-9659-93500A474F7FQ34125116-A352B1E5-E934-4A6C-BF6D-60DCFAE89C4BQ34223052-9CAE7D62-A1B0-4D97-ABFF-953511709991Q35614156-30457489-CB48-4426-AB17-A16532774055Q36015579-3EA9201B-9681-4E35-9FB0-11B17D84E99BQ36252786-1E222AF0-0764-4702-AA5F-C6F8D26BEF84Q37122707-0BA17FD2-4306-4809-BE10-4252A95EB112Q37999106-F15A5558-DBEC-420D-8F17-0B9BF8F90DB3Q38056852-F2F3596C-878E-4D7F-9640-22E63925669FQ38092819-850F8A34-516A-4F93-8850-E138715788FDQ38146898-F2A9428D-6137-4D8D-B889-5BF139B69717Q38174986-9DB020AA-3AC2-459C-9F55-037970E1F98AQ38190016-A97768C5-927E-4E38-8CFC-39D89C0E1A31Q38658203-2BDAAB4D-C4BA-4862-900E-83274F9959F6Q39265062-A867481F-ADCC-44C0-828B-DAC2BF8EC5F0Q39282544-F7FB22E1-1ECE-40BF-8D74-72C4898FC465Q39604782-4A97F632-44F7-48BD-BE8E-EC7F2ABE431CQ48400446-04EF77EA-65D7-47E4-9827-C9C3E4CFD628
P2860
Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic potential of targe ...... atment of Parkinson's disease.
@en
Therapeutic potential of targe ...... atment of Parkinson's disease.
@nl
type
label
Therapeutic potential of targe ...... atment of Parkinson's disease.
@en
Therapeutic potential of targe ...... atment of Parkinson's disease.
@nl
prefLabel
Therapeutic potential of targe ...... atment of Parkinson's disease.
@en
Therapeutic potential of targe ...... atment of Parkinson's disease.
@nl
P2860
P921
P1476
Therapeutic potential of targe ...... eatment of Parkinson's disease
@en
P2093
Susan Duty
P2860
P304
P356
10.1111/J.1476-5381.2010.00882.X
P407
P50
P577
2010-09-01T00:00:00Z